Stocks · News reference
Nanobiotix S.A. successfully raised $100 million through a global equity offering, with shares priced at €33.60 each.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Nanobiotix reported updated clinical results from its ongoing Phase 1 Study 1100, evaluating JNJ-1900 (NBTXR3) in patients with anti-PD-1-resistant advanced primary cutaneous melanoma.
The HNSCC market is projected to grow from $850 million in 2025 to $2.56 billion by 2036 (10.5% CAGR), driven by HPV-targeted vaccines, checkpoint inhibitors, and biomarker-led patient selection. The US will remain the largest market at $2.082 billion. Key therapies include KEYTRUDA and OPDIVO, with emerging candidates like petosemtamab and amivantamab showing promise in clinical development.
Nanobiotix (NASDAQ:NBTX) reported quarterly losses of $(0.82) per share. This is a 583.33 percent decrease over losses of $(0.12) per share from the same period last year. The company reported $6.533 million in sales